Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

AI Summary

Biogen is pushing forward with its late-stage trial for an Alzheimer's drug, despite earlier disappointing data. The development is a significant step in the ongoing search for effective treatments for the disease.